Now showing items 1-10 of 141
Knowledge and acceptability of HAART among TB patients in Durban, South Africa.
(Taylor & Francis., 2005)
From October 2002 to February 2003, we conducted semi-structured interviews on knowledge of HIV, antiretroviral treatment, and willingness to participate in voluntary counselling and testing and HAART with 54 consenting ...
Antiretroviral prophylaxis for HIV prevention reaches a key milestone.
No abstract available.
HIV-prevention science at a crossroads: advances in reducing sexual risk.
(Lippincott Williams & Wilkins., 2009)
Purpose of review—We review the current state of evidence-based prevention strategies for reducing sexual transmission of HIV. The combined programmatic and scientific efforts through 2008 to reduce sexual transmission of ...
Disclosure of HIV status: experiences of patients enrolled in an integrated TB and HAART programme in South Africa.
(NISC & Taylor & Francis, 2009)
The convergence between the tuberculosis (TB) and HIV epidemics has led to studies investigating strategies for integrated HIV and TB care. We present the experiences of a cohort of 17 patients enrolled in the first ...
HIV treatment in South Africa: overcoming impediments to get started.
No abstract available.
Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy.
(Oxford University Press., 2013)
Background. Eight decades ago, the ratio of monocytes to lymphocytes (hereafter, the “ML ratio”) was noted to affect outcomes of mycobacterial infection in rabbits. Recent transcriptomic studies support a role for relative ...
Patients’ readiness to start highly active antiretroviral treatment for HIV.
(BMJ publishing group., 2005)
Assessing whether patients are ready to start antiretroviral treatment may improve HIV prevention and treatment outcomes.
Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.
(Oxford University Press., 2011)
The antiretroviral agent, tenofovir, formulated as a vaginal microbicide gel, reduces human immunodeficiency virus (HIV) acquisition by 39% in women. This study assessed the role of preexisting immune activation in ...
Topical microbicides - What's new?
(Lippincott Williams & Wilkins., 2013)
Topical microbicides are an important, promising but complex HIV prevention technology under development. After 11 disappointing effectiveness trial outcomes of 6 candidate products (some tested as multiple doses and ...
(Hindawi Publishing Corporation., 2010)
The intersecting HIV and Tuberculosis epidemics in countries with a high disease burden of both infections pose many challenges and opportunities. For patients infected with HIV in high TB burden countries, the diagnosis ...